BRAF and colorectal carcinoma: Our screening for synthetic lethality with pevonedistat in CRC cell lines highlighted multiple candidate drug target genes that displayed limited nominal overlap across cell lines but consistent convergence on the EGFR pathway, irrespective of the KRAS/BRAF mutational status.